Dipyridamole tid
Phase 3Small molecule
Dipyridamole tid is one of 22 small molecule programs targeting Restless Legs Syndrome. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Restless Legs Syndrome
#DrugCompanyPhaseTrials
1Neupro
UCBApproved
Mirapex
Boehringer IngelheimApproved
Requip Xl
GGlaxo Dba Glaxosmithkline
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Dostinex
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Avelox
BayerApproved
Injectafer
AAmerican Regent, Inc.
Approved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Topamax
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dipyridamole tid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- YYunfeng Xia